Biotech firms increase product launches as capital markets improve

A growing number of biotech companies are bringing new medicines to market, a trend analysts link to improving capital markets.

While the majority of approved drugs still come from large pharmaceutical firms, smaller biotechs are increasingly tackling the commercial side of drug development.

Analysts note that launching drugs remains difficult, especially with payer restrictions, but many biotechs are better prepared by focusing on patient, physician and payer needs.

Overall, the market outlook is optimistic as better financing conditions appear to support more frequent product launches from smaller players.